Cargando…

Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care

AIM: Whether glucose sensor alarms improve metabolic control and are accepted by individuals with diabetes is unclear. Here, we investigated whether switching from a standard flash glucose monitoring system (FGM1) to a system equipped with hypo- and hyperglycemia alarms (FGM2) improves glycemic cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boscari, Federico, Ferretto, Sara, Cavallin, Francesco, Fadini, Gian Paolo, Avogaro, Angelo, Bruttomesso, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156464/ https://www.ncbi.nlm.nih.gov/pubmed/35416537 http://dx.doi.org/10.1007/s00592-022-01884-1

Ejemplares similares

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown
por: Boscari, Federico, et al.
Publicado: (2021)

Glycemic control after switching to faster aspart in adults with type 1 diabetes
por: Fadini, G. P., et al.
Publicado: (2022)

Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance
por: Boscari, F., et al.
Publicado: (2021)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives
por: Boscari, Federico, et al.
Publicado: (2021)

Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
por: Morieri, Mario Luca, et al.
Publicado: (2022)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
por: Longato, Enrico, et al.
Publicado: (2022)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Assessment of Glucose Lowering Medications’ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes
por: Sciannameo, Veronica, et al.
Publicado: (2022)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Real-Time Improvement of Continuous Glucose Monitoring Accuracy: The smart sensor concept
por: Facchinetti, Andrea, et al.
Publicado: (2013)

Similar effectiveness of dapagliflozin and GLP‐1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions
por: Kropff, J, et al.
Publicado: (2015)

Alarm performance in a novel continuous glucose monitor
por: Gottlieb, R, et al.
Publicado: (2011)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Infection Rates and Impact of Glucose Lowering Medications on the Clinical Course of COVID-19 in People with Type 2 Diabetes: A Retrospective Observational Study
por: Mannucci, Francesca, et al.
Publicado: (2022)

Flash glucose monitoring system in special situations
por: Rigon, Fernanda Augustini, et al.
Publicado: (2022)

Using flash glucose monitoring in pregnancies in routine care of patients with gestational diabetes mellitus: a pilot study
por: Bastobbe, Sophie, et al.
Publicado: (2023)

Monitoring of Diabetes Mellitus Using the Flash Glucose Monitoring System: The Owners’ Point of View
por: Re, Mariachiara, et al.
Publicado: (2023)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Accuracy of a flash glucose monitoring system in dogs with diabetic ketoacidosis
por: Malerba, Eleonora, et al.
Publicado: (2019)

Analysis Estimating the Potential Cost Impact of Utilizing Flash Glucose Monitoring with Optional Alarms in Swedish Adults with Diabetes with Impaired Awareness of Hypoglycaemia, Using Intensive Insulin
por: Blissett, Deirdre B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_udq6pcg27206jisb98jhok27v6